Study explains how cancer drug triggers diabetes onset

04/3/2012 | International Business Times

Rapamycin, a drug used by organ transplant and cancer patients, appears to interact with the Yin Yang 1 gene and disrupt the insulin-signaling pathway in the liver and muscles, which results in the onset of diabetes in mice, researchers reported in Cell Metabolism. The findings suggest that rapamycin-treated patients may also want to take antidiabetes drugs that boost insulin sensitivity.

View Full Article in:

International Business Times

Published in Brief:

SmartBrief Job Listings for Health Care